Loss-of-function genomic variants with impact on liver-related blood traits highlight potential therapeutic targets for cardiovascular disease

Jonas B. Nielsen, Oren Rom, Ida Surakka, Sarah E. Graham, Wei Zhou, Lars G. Fritsche, Sarah A. Gagliano Taliun, Carlo Sidore, Yuhao Liu, Maiken E. Gabrielsen, Anne Heidi Skogholt, Brooke N. Wolford, William Overton, Whitney Hornsby, Akua Acheampong, Austen Grooms, Tanmoy Roychowdhury, Amanda M. Schaefer, Gregory J. M. Zajac, Luis Villacorta, Jifeng Zhang, Ben Brumpton, Mari Løset, Vivek Rai, Kent D. Taylor, Nicholette D. Palmer, Yii-Der Chen, Seung Hoan Choi, Steven A. Lubitz, Patrick T. Ellinor, Kathleen C. Barnes, Michelle Daya, Nicholas Rafaels, Scott T. Weiss, Jessica Lasky‐Su, Russell P. Tracy, Ramachandran S. Vasan, L. Adrienne Cupples, Rasika A. Mathias, Lisa R. Yanek, Lewis C. Becker, Patricia A. Peyser, Lawrence F. Bielak, Jennifer A. Smith, Stella Aslibekyan, Bertha Hildalgo, Donna K. Arnett, Marguerite R. Irvin, James G. Wilson, Solomon K. Musani, Adolfo Correa, Stephen S. Rich, Xiuqing Guo, Jerome I. Rotter, Barbara A. Konkle, Jill M. Johnsen, Allison E. Ashley‐Koch, Marilyn J. Telen, Vivien Sheehan, John Blangero, Joanne E. Curran, Juan M. Peralta, Courtney G. Montgomery, Wayne H-h Sheu, Ren-Hua Chung, Karen Schwander, Mehdi Nouraie, Victor R. Gordeuk, Yingze Zhang, Charles Kooperberg, Alexander P. Reiner, Rebecca D. Jackson, Eugene R. Bleecker, Deborah A. Meyers, Xingnan Li, Sayantan Das, Ketian Yu, Jonathon LeFaive, Albert V. Smith, Tom Blackwell, Daniel Taliun, Sebastian Zöllner, Lukas Forer, Sebastian Schoenherr, Christian Fuchsberger, Anita Pandit, Matthew Zawistowski, Sachin Kheterpal, Chad M. Brummett, Pradeep Natarajan, David Schlessinger, Seunggeun Lee, Hyun Min Kang, Francesco Cucca, Oddgeir L. Holmen, Bjørn Olav Åsvold, Michael Boehnke, Sekar Kathiresan, Gonçalo R. AbecasisbioRxiv 2019 · DOI

TL;DR

This study identifies rare genetic variants that lower LDL cholesterol without negatively impacting liver function, suggesting they could be promising therapeutic targets for cardiovascular disease. By analyzing a large dataset and performing in vitro experiments, the researchers pinpointed ZNF529 as a novel regulator of LDL cholesterol, offering a potential new avenue for treating hypercholesterolemia.

What Problem Does This Paper Address?

Cardiovascular diseases (CVDs) are a leading cause of death globally, and lowering circulating lipids is a key strategy to reduce this risk. However, some existing treatments for CVD can inadvertently increase the risk of fatty liver disease or other metabolic disorders. This presents a challenge: how can we effectively reduce CVD risk without exacerbating metabolic health issues? The authors aim to address this by identifying novel therapeutic targets that can lower CVD risk factors, specifically LDL cholesterol, while avoiding adverse effects on liver function.

Methods

The researchers employed a multi-pronged approach for genomic discovery:

  • Low-coverage whole-genome sequencing and targeted genotyping: This allowed them to capture a broad range of genetic variation.
  • Deep genotype imputation: Using the TOPMed reference panel, they enhanced the accuracy and coverage of their genetic data.
  • Genome-wide association study (GWAS) meta-analysis: This statistical method was used to identify associations between genetic variants and 12 different liver-related blood traits (including liver enzymes, blood lipids, and iron metabolism markers) across multiple large cohorts.
  • Phenome-wide association studies (PheWAS): This approach examined the association of identified variants with a wide range of disease outcomes to assess potential side effects.
  • In vitro studies: To experimentally validate findings, they used human hepatoma cells (HepG2) to investigate the functional impact of a specific gene (ZNF529) on LDL uptake.

Datasets

The study utilized data from several large population-based cohorts:

  • HUNT Study (Nord-Trøndelag Health Study, Norway): This cohort provided a substantial dataset for initial discovery and association testing.
  • Biobank Japan (BBJ): This Japanese registry contributed to the trans-ancestry meta-analysis.
  • SardiNIA cohort: This Sardinian cohort was also included in the trans-ancestry meta-analysis.
  • UK Biobank: This large dataset was used for phenome-wide association studies to assess the impact of variants on various disease phenotypes.

Key Insights and Ideas

  • Targeting LDL-C without liver harm: The core idea is to find genetic variants that lower LDL cholesterol but don't negatively affect liver enzymes. This is crucial for developing safer and more effective CVD treatments.
  • Loss-of-function (LoF) variants as drug targets: The study highlights that rare LoF variants can have significant impacts on traits like LDL-C. These variants can serve as valuable clues for identifying genes whose inhibition might mimic a protective genetic effect.
  • ZNF529 as a novel regulator of LDL-C: The identification of a novel LoF variant in ZNF529 that significantly lowers LDL-C without affecting liver enzymes is a major finding. The subsequent in vitro work demonstrating its role in upregulating LDLR and increasing LDL-C uptake provides strong evidence for its therapeutic potential.
  • The power of multi-phenotype analysis: By simultaneously considering liver function and CVD-related traits, the researchers could identify variants with a desirable profile (lowering LDL-C, not harming the liver), which might be missed in single-trait analyses.

Key Results

  • The study identified 88 likely causal protein-altering variants associated with one or more liver-related blood traits.
  • Among these, several loss-of-function (LoF) variants were found to reduce LDL-C without increasing the risk of liver disease or diabetes.
  • A novel LoF variant, ZNF529:p.K405X, was strongly associated with decreased LDL-C (P=1.3x10⁻⁸) and showed no association with liver enzymes or blood glucose.
  • Experimental silencing of ZNF529 in human hepatocytes led to a significant upregulation of LDL receptor (LDLR) and increased LDL-C uptake.
  • The study also confirmed known associations and identified other promising variants in genes like APOB, LPL, and CETP.

Limitations and Future Work

  • Replication challenges for rare variants: The study notes that detecting associations with very rare variants can be challenging due to limited statistical power, as exemplified by the replication attempt for ZNF529:p.K405X in the MGI cohort where only one heterozygous carrier was found.
  • Functional validation of all variants: While ZNF529 was extensively studied in vitro, the functional mechanisms for all 88 identified variants were not explored.
  • Further mechanistic studies for ZNF529: While the study demonstrates ZNF529's role in regulating LDLR and LDL-C uptake, further research is needed to fully elucidate the precise molecular mechanisms.
  • Clinical translation: The identified variants and genes represent potential therapeutic targets, but significant further research and clinical trials are necessary to translate these findings into actual treatments.
  • Exploring other cardiometabolic diseases: The authors suggest that future studies should investigate the role of these genes in other cardiometabolic diseases to better predict outcomes and disease progression.

Summary updated

Abstract

SUMMARY Cardiovascular diseases (CVD), and in particular cerebrovascular and ischemic heart diseases, are leading causes of death globally. 1 Lowering circulating lipids is an important treatment strategy to reduce risk. 2,3 However, some pharmaceutical mechanisms of reducing CVD may increase risk of fatty liver disease or other metabolic disorders. 4,5,6 To identify potential novel therapeutic targets, which may reduce risk of CVD without increasing risk of metabolic disease, we focused on the simultaneous evaluation of quantitative traits related to liver function and CVD. Using a combination of low-coverage (5×) whole-genome sequencing and targeted genotyping, deep genotype imputation based on the TOPMed reference panel 7 , and genome-wide association study (GWAS) meta-analysis, we analyzed 12 liver-related blood traits (including liver enzymes, blood lipids, and markers of iron metabolism) in up to 203,476 people from three population-based cohorts of different ancestries. We identified 88 likely causal protein-altering variants that were associated with one or more liver-related blood traits. We identified several loss-of-function (LoF) variants reducing low-density lipoprotein cholesterol (LDL-C) or risk of CVD without increased risk of liver disease or diabetes, including variants in known lipid genes (e.g. APOB , LPL ). A novel LoF variant, ZNF529 :p.K405X, was associated with decreased levels of LDL-C (P=1.3×10 −8 ) but demonstrated no association with liver enzymes or non-fasting blood glucose levels. Silencing of ZNF529 in human hepatocytes resulted in upregulation of LDL receptor (LDLR) and increased LDL-C uptake in the cells, suggesting that inhibition of ZNF529 or its gene product could be used for treating hypercholesterolemia and hence reduce the risk of CVD. Taken together, we demonstrate that simultaneous consideration of multiple phenotypes and a focus on rare protein-altering variants may identify promising therapeutic targets.
BibTeX
@misc{nielsen2019loss,
  author = {Jonas B. Nielsen and Oren Rom and Ida Surakka and Sarah E. Graham and Wei Zhou and Lars G. Fritsche and Sarah A. Gagliano Taliun and Carlo Sidore and Yuhao Liu and Maiken E. Gabrielsen and Anne Heidi Skogholt and Brooke N. Wolford and William Overton and Whitney Hornsby and Akua Acheampong and Austen Grooms and Tanmoy Roychowdhury and Amanda M. Schaefer and Gregory J. M. Zajac and Luis Villacorta and Jifeng Zhang and Ben Brumpton and Mari Løset and Vivek Rai and Kent D. Taylor and Nicholette D. Palmer and Yii-Der Chen and Seung Hoan Choi and Steven A. Lubitz and Patrick T. Ellinor and Kathleen C. Barnes and Michelle Daya and Nicholas Rafaels and Scott T. Weiss and Jessica Lasky‐Su and Russell P. Tracy and Ramachandran S. Vasan and L. Adrienne Cupples and Rasika A. Mathias and Lisa R. Yanek and Lewis C. Becker and Patricia A. Peyser and Lawrence F. Bielak and Jennifer A. Smith and Stella Aslibekyan and Bertha Hildalgo and Donna K. Arnett and Marguerite R. Irvin and James G. Wilson and Solomon K. Musani and Adolfo Correa and Stephen S. Rich and Xiuqing Guo and Jerome I. Rotter and Barbara A. Konkle and Jill M. Johnsen and Allison E. Ashley‐Koch and Marilyn J. Telen and Vivien Sheehan and John Blangero and Joanne E. Curran and Juan M. Peralta and Courtney G. Montgomery and Wayne H-H Sheu and Ren-Hua Chung and Karen Schwander and Mehdi Nouraie and Victor R. Gordeuk and Yingze Zhang and Charles Kooperberg and Alexander P. Reiner and Rebecca D. Jackson and Eugene R. Bleecker and Deborah A. Meyers and Xingnan Li and Sayantan Das and Ketian Yu and Jonathon LeFaive and Albert V. Smith and Tom Blackwell and Daniel Taliun and Sebastian Zöllner and Lukas Forer and Sebastian Schoenherr and Christian Fuchsberger and Anita Pandit and Matthew Zawistowski and Sachin Kheterpal and Chad M. Brummett and Pradeep Natarajan and David Schlessinger and Seunggeun Lee and Hyun Min Kang and Francesco Cucca and Oddgeir L. Holmen and Bjørn Olav Åsvold and Michael Boehnke and Sekar Kathiresan and Gonçalo R. Abecasis and Y. Eugene Chen},
  title = {{Loss-of-function genomic variants with impact on liver-related blood traits highlight potential therapeutic targets for cardiovascular disease}},
  year = {2019},
  doi = {10.1101/597377},
  howpublished = {bioRxiv},
}
Figure